European Hematology Association: AHL2011: Outstanding Disease Control With a Minimized BEACOPP Exposure and Toxicity in Patients With Advanced Hodgkin Lymphoma

USA - English

• USA - español
• USA - Français
• USA - Deutsch

STOCKHOLM, June 15, 2018 /PRNewswire/ --

Six cycles of BEACOPP provide a better long-term disease control than ABVD in advanced Hodgkin lymphoma but is associated to more frequent hematological toxicity and a higher risk of myelodysplasia/acute leukemia and infertility. The AHL2011 demonstrate that a de-escalation treatment with a switch from BEACOPP to ABVD is possible after two cycles of BEACOPP in most patients (84%) who reached a negative PET2 maintaining the same level of disease control and drastically reducing the risk of the treatment toxicity compared to patients who received the standard six cycles of BEACOPP. So, without any new drug, this approach based on the early response assessment using functional imaging (PET) improve the management of patients with advanced Hodgkin lymphoma, providing a better balance tolerability/efficacy of BEACOPP-based treatment and a better patient outcome (5y-PFS>85% and 5y-OS>95%) than ABVD.

     (Logo: http://mma.prnewswire.com/media/622259/EHA_Logo.jpg )

Presenter:  Dr Olivier Casasnovas 

Affiliation: Department of Hematology, Dijon, France 

Topic: FINAL ANALYSIS OF THE AHL2011 RANDOMIZED PHASE III LYSA STUDY COMPARING AN EARLY PET DRIVEN TREATMENT DE-ESCALATION TO A NOT PET-MONITORED STRATEGY IN PATIENTS WITH ADVANCED STAGES HODGKIN LYMPHOMA

Abstract S110 will be presented by Olivier Casasnovas on Friday, June 15, 11:30-11:45 in Room A2.

About the EHA Annual Congress
Every year in June, EHA organizes its Annual Congress in a major European city. After five years, the congress returns to Stockholm. The Congress is aimed at health professionals working in or interested in the field of hematology.

The scientific program topics range from stem cell physiology and development, to leukemia; lymphoma; diagnosis and treatment; red blood cells; white blood cells and platelet disorders; hemophilia and myeloma; thrombosis and bleeding disorders as well as transfusion and stem cell transplantation.

Embargo

Please note that our embargo policy applies to all selected abstracts in the Press Briefings. For more information check our Congress Media Guidelines here.

Website: www.ehaweb.org

SOURCE European Hematology Association